Pro-inflammatory mediators and signaling proteins

Pro-inflammatory mediators and signaling proteins represent a broad and heterogeneous class of molecules that orchestrate the body's response to injury and infection. This category includes secreted signaling proteins such as cytokines (e.g., Tumor Necrosis Factor-alpha, Interleukin-1, and Interleukin-6) and chemokines, as well as intracellular signaling components like the Janus kinase (JAK) family and the Nuclear Factor-kappa B (NF-κB) pathway (StatPearls, NBK493173). These molecules function by binding to specific cell-surface receptors, initiating cascades that lead to the recruitment of leukocytes and the activation of genes involved in the immune response (PubMed, PMC3492721). While essential for acute defense, their chronic or excessive production is a primary driver of autoimmune diseases, chronic inflammatory conditions, and systemic inflammatory response syndromes (Nature Reviews Immunology, 2018). Pharmacological intervention often targets these pathways using monoclonal antibodies to neutralize cytokines or small molecules to inhibit signaling kinases (PubMed, PMC7121071). However, because these mediators are integral to normal immunity, their inhibition can lead to significant safety concerns, including an increased susceptibility to opportunistic infections and the reactivation of latent diseases (NIH, MedlinePlus).

Other names

Inflammatory mediatorsPro-inflammatory cytokinesInflammatory signaling moleculesInflammatory cascade components

Drugs targeting these mediators typically function through several mechanisms: monoclonal antibodies neutralize circulating cytokines to prevent receptor binding; receptor antagonists competitively block signaling; and small molecule inhibitors target intracellular kinases like JAKs to prevent the phosphorylation and activation of transcription factors (PubMed, PMC7121071).